DNA Damage Burden Causes Selective CUX2 Neuron Loss in Neuroinflammation

Why It Matters

The findings identify DNA‑repair pathways as actionable targets to protect upper‑layer cortical neurons and potentially slow brain atrophy in multiple sclerosis.

Key Takeaways

• CUX2 loss increases DNA damage in cortical L2/3 neurons
• MS patients show elevated γH2AX, 53BP1 foci in L2/3 ENs
• Mouse models reveal selective L2/3 neuron loss after demyelination
• CUX2 and ATF4 cooperate to repair DNA via RPA3
• IFNγ-driven inflammation worsens L2/3 neuron vulnerability

Pulse Analysis

Neurodegeneration in multiple sclerosis has long been linked to inflammatory demyelination, yet the molecular triggers of cortical neuron loss remain elusive. Recent research underscores that accumulated DNA lesions—single‑strand breaks, double‑strand breaks, and oxidative base modifications—activate a broad DNA‑damage response (DDR) in vulnerable neurons. In MS patients, upper‑layer excitatory neurons (L2/3ENs) display heightened γH2AX and 53BP1 foci, markers of unrepaired DNA damage, correlating with cortical thinning and cognitive decline. This DNA‑damage burden distinguishes these neurons from deeper cortical layers, suggesting a layer‑specific susceptibility that may drive progressive brain atrophy.

The study delves into the role of the transcription factor CUX2, a gene associated with MS risk, and its partner ATF4 in safeguarding L2/3ENs. Mouse models with pan‑cortical demyelination (DTA and Myrf‑cKO) recapitulate human findings, showing >10% loss of CUX2‑positive neurons after weeks of neuroinflammation. Genetic ablation of Cux2 disrupts base‑excision repair and double‑strand break pathways, while double knockouts with Atf4 exacerbate DNA‑damage signatures and neuronal death. Conversely, lentiviral overexpression of CUX2 or ATF4 in human neuroblastoma cells and induced neurons accelerates repair of oxidative lesions, restores RPA3 transcription, and boosts non‑homologous end‑joining efficiency, highlighting a synergistic repair axis.

These insights open new therapeutic avenues focused on enhancing neuronal DNA‑repair capacity. Pharmacologic activation of CUX2‑ATF4 signaling or up‑regulation of downstream effectors like RPA3 could fortify upper‑cortical neurons against inflammatory oxidative stress. Moreover, the link between IFNγ‑driven inflammation and DDR exhaustion suggests that combining immunomodulation with DNA‑repair enhancers may more effectively preserve cortical integrity in MS. Future clinical trials will need to assess safety and efficacy of such strategies, potentially extending benefits to other neurodegenerative disorders where DNA damage is a central pathology.